Sofosbuvir & Sofosbuvir/Velpatasvir Exporter and Supplier in India
We are looking for a dependable generic hepatitis C source, and this is the page for buyers who say exactly that. M Care Exports is an India-based merchant-exporter (trading since 2003) supplying sofosbuvir 400mg and the pan-genotypic sofosbuvir 400mg + velpatasvir 100mg fixed-dose combination from WHO-GMP-listed manufacturing lines. We serve importers, distributors and national hepatitis-elimination programme buyers across Africa, South East Asia, the CIS and the GCC.
Wholesale sofosbuvir supply for HCV-elimination programmes and DAA distributors
India is the origin point for most of the world's generic direct-acting antivirals, a position built on Gilead's 2014 to 2017 voluntary licences to Indian manufacturers. M Care Exports works inside that landscape as a trading house, not a factory: we consolidate the single-molecule sofosbuvir tablet and the sofosbuvir/velpatasvir pan-genotypic combination across a broad hepatitis C DAA catalogue and ship them against your tender, restocking or programme forecast. We do not hold WHO-PQ or WHO-GMP ourselves (those belong to the manufacturer); we supply from lines that carry them and compile the export dossier alongside you.
Two dosage forms, one supply channel
Sofosbuvir 400mg tablets and the sofosbuvir 400mg + velpatasvir 100mg fixed-dose combination sourced together, so a mixed genotype-1-to-6 programme order ships from a single co-ordinated release.
Reference brands held across the catalogue
Reference brands include Hepcinat and Resof on the single-molecule sofosbuvir side, and Velpanat and Velasof for the sofosbuvir/velpatasvir combination. Brand is buyer-reference only; we quote to your registered or preferred label.
MOQ set by the manufacturer's batch release
Order minimums follow the source manufacturer's batch-release quantity rather than an arbitrary house figure. Tell us your programme volume and we confirm the achievable minimum against current production.
Pricing on request, tied to source and batch
Sofosbuvir pricing moves with API cost, pack configuration and volume, so we quote per enquiry rather than publishing a rate. Send genotype coverage, strength split and destination for a firm offer.
Sofosbuvir at a glance: strengths, class and regulatory context
Active ingredient
Sofosbuvir, a nucleotide analogue NS5B RNA-polymerase inhibitor, supplied alone or co-formulated with the NS5A inhibitor velpatasvir.
Strengths stocked
Sofosbuvir 400mg film-coated tablet; sofosbuvir 400mg + velpatasvir 100mg fixed-dose tablet. Both typically packed as 28-tablet bottles for a monthly treatment course.
Drug class and ATC
Direct-acting antiviral, NS5B polymerase inhibitor. ATC J05AP08 for sofosbuvir; J05AP55 for the sofosbuvir/velpatasvir combination.
Genotype coverage
Single-molecule sofosbuvir is genotype-dependent when paired with other DAAs. The velpatasvir combination is pan-genotypic, covering HCV genotypes 1 through 6.
Regulatory standing
On the WHO Model List of Essential Medicines. Multiple Indian sofosbuvir/velpatasvir lines hold WHO prequalification; M Care's own credential is ISO 9001:2015 as the exporting trading entity.
Handling
Store below 30°C in original packaging, protected from moisture. A stable oral solid requiring no cold chain, which simplifies programme-scale distribution to warm-climate markets.
Buyers we serve for sofosbuvir and the velpatasvir combination
Sofosbuvir demand in our export markets is programme-led as much as pharmacy-led. Whoever you are in the chain, we quote to your registration and volume rather than to a shelf price.
National hepatitis-elimination programmes
Ministries and central medical stores running WHO-aligned HCV-elimination targets need pan-genotypic first-line supply at predictable cadence. We forecast against multi-month treatment cohorts.
Global Fund-adjacent and tender buyers
Institutional and donor-funded procurement demands documented manufacturer prequalification and a clean CoPP. We supply from WHO-PQ-listed lines and assemble the tender file with you.
Importers and DAA distributors
Distributors in Africa, South East Asia and the CIS restocking a hepatitis C line get consolidated sofosbuvir and velpatasvir-combination shipments under one export release.
Hospital and specialty-pharmacy groups
Liver-clinic and infectious-disease pharmacy networks sourcing a registered pan-genotypic option receive quantities matched to their dispensing schedule.
Safety-critical information for procurement and regulatory teams
This is professional reference context for buyers and regulatory reviewers, not patient advice or a substitute for the approved product information. The dosing note below simply frames how the molecule is used: as a once-daily oral solid, the sofosbuvir/velpatasvir combination is typically taken as one tablet daily for 12 weeks, and single-molecule sofosbuvir is always given inside a combination DAA regimen, never alone.
HBV reactivation carries a boxed warning. Hepatitis B virus can reactivate in HCV/HBV co-infected patients during or after direct-acting antiviral therapy, in some cases causing fulminant hepatitis, liver failure and death. Prescribers must test for HBsAg and anti-HBc before starting treatment. Serious bradycardia has been reported, including fatal cardiac arrest and cases needing a pacemaker, when a sofosbuvir-containing regimen is co-administered with amiodarone; this combination is not recommended.
Potent P-glycoprotein inducers such as rifampicin and St John's Wort markedly lower sofosbuvir plasma levels and can cause treatment failure, so they must not be co-administered. Where a regimen adds ribavirin (used for some cirrhotic genotypes), all ribavirin contraindications, including pregnancy, apply in full. These warnings should be reflected in the destination-market labelling and dossier.
Written for professional buyers and importers, not as medical advice. Prescribing decisions sit with the treating clinician and the approved label in your market.
Export and registration documents we compile with you
A hepatitis C DAA order clears customs and product registration only with a complete, consistent file. As your merchant-exporter we assemble the following alongside the manufacturer, honest about what originates where.
CTD dossier support
We co-ordinate the Common Technical Document for sofosbuvir and the velpatasvir combination with the manufacturer and compile it alongside your registration agent for the destination authority.
CoPP and free-sale certification
Certificate of Pharmaceutical Product and free-sale documentation are drawn from the manufacturing site, with M Care handling the export-side collation and legalisation.
Batch CoA and specifications
Each shipment carries the manufacturer's certificate of analysis, finished-product specification and, on request, the stability summary for your regulatory file.
Export shipping set
Commercial invoice, packing list, certificate of origin and, where required, GMP evidence from the source line accompany every consignment for smooth customs clearance.
Serialisation and artwork
We co-ordinate track-and-trace serialisation and destination-market pack artwork with the manufacturer so labelling matches your registration and language requirements.
Molecules buyers source alongside Sofosbuvir.
How ordering works.
- Send your enquiry Share the strengths (sofosbuvir 400mg and/or the 400/100mg combination), genotype coverage required, quantity and destination market so we can scope the order accurately.
- Receive a sourced quotation We confirm availability from a WHO-GMP-listed line, the manufacturer batch-release minimum and a firm price on request, with reference brand options if you need them.
- Approve documentation We align the CTD dossier, CoPP, CoA and shipping set with your registration agent before dispatch, so nothing stalls at the destination authority.
- Dispatch and track On confirmation we co-ordinate release, ambient shipping and export paperwork, and keep you updated through to customs clearance at your port.
Sofosbuvir supply, the specific questions.
Do you supply both sofosbuvir alone and the sofosbuvir/velpatasvir combination?
Yes. We supply sofosbuvir 400mg single-molecule tablets and the pan-genotypic sofosbuvir 400mg + velpatasvir 100mg fixed-dose combination. The single-molecule tablet is used inside genotype-specific DAA regimens, while the velpatasvir combination covers HCV genotypes 1 to 6 in a single tablet, which is why programme buyers often standardise on it.
Is the sofosbuvir you supply WHO-prequalified?
Several Indian sofosbuvir/velpatasvir lines hold WHO prequalification, and we supply from WHO-GMP-listed and, where you require it, WHO-PQ-listed manufacturing sites. To be clear about who holds what: the prequalification belongs to the manufacturer, not to M Care. M Care's own credential is ISO 9001:2015 as the exporting trading house. Tell us if your tender specifically requires a WHO-PQ-listed source and we will quote accordingly.
What is the minimum order quantity?
There is no fixed house minimum. The MOQ follows the source manufacturer's batch-release quantity for the strength and pack you need. Send us your programme or restocking volume and we confirm the achievable minimum against current production.
Which reference brands map to the SKUs you hold?
For buyer reference, our catalogue spans brands such as Hepcinat and Resof on the single-molecule sofosbuvir side and Velpanat and Velasof for the sofosbuvir/velpatasvir combination. We name these only so you can match a familiar label; we quote to your own registered or preferred brand rather than selling a specific retail pack.
Can you supply against a government or donor-funded tender?
Yes. We regularly serve national hepatitis-elimination programmes and Global Fund-adjacent procurement. We supply from prequalification-listed manufacturing lines and compile the CTD dossier, CoPP and batch documentation with you so the tender file is complete and consistent. Share the tender reference and required source standard for a scoped offer.
Does sofosbuvir need cold-chain shipping?
No. Both the single-molecule tablet and the velpatasvir combination are stable oral solids stored below 30°C in original packaging, with no refrigeration required. That ambient handling profile simplifies distribution to warm-climate programme markets across Africa, the GCC and South East Asia.
Request a sofosbuvir or sofosbuvir/velpatasvir quotation
Tell us the strengths, genotype coverage, quantity and destination market. We will confirm a WHO-GMP-listed source, the manufacturer batch-release minimum and a firm price on request, and compile the export dossier alongside you.